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Background: The influence of serous retinal detachment (SRD) on visual acuity, macular sensitivity, and macular
thickness is unclear after intravitreal injection of triamcinolone acetonide (IVTA) for macular edema with branch
retinal vein occlusion (BRVO).
Methods: Twenty-one eyes of 21 BRVO patients with macular edema received IVTA. Patients were divided into two
groups by optical coherence tomography findings: 11 patients who had cystoid macular edema (CME) with SRD
(SRD (+) group) and 10 patients who had CME without SRD (SRD (−) group). Microperimetry was performed with a
Micro Perimeter 1 before and at 3 and 6 months after IVTA. Macular thickness was measured by optical coherence
tomography. We exchanged the superior and inferior regions to separate the regions into those with and without
occlusion. As a result, the superior region was always the occluded region and the inferior region was non-
occluded.
Results: In both the SRD (−) group and the SRD (+) group, the mean macular thickness within the central 4° field
and the 10° and 20° fields of the occluded region decreased significantly from baseline to 3 and 6 months after
IVTA (all P <0.01). Visual acuity also improved significantly in both groups from baseline to 3 and 6 months after
IVTA (both P <0.05). In both groups, the mean macular sensitivity (measured with by microperimetry) within the
central 4° field and the 10° and 20° fields of the occluded region showed a significant increase from baseline to 3
and 6 months after IVTA (all P <0.05). The trend profiles of macular thickness within the 10° and 20° fields of the
occluded region showed significant differences, but there were no significant differences with respect to the trend
profiles of visual acuity and macular sensitivity within the central 4° field and the 10° and 20° fields of the occluded
region.
Conclusions: These results suggest that IVTA may achieve more marked improvement of macular morphology in
BRVO patients with SRD than in those without SRD, while this therapy may have a similar effect on macular
function in BRVO patients with or without SRD.* Correspondence: noma-hide@umin.ac.jp
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Branch retinal vein occlusion (BRVO) is a common ret-
inal vascular disease that often leads to macular edema,
which is the chief reason for visual impairment in
BRVO patients [1,2]. An increase of pressure and re-
duction of blood flow in the macular capillaries can
lead to dysfunction of the endothelial blood-retinal bar-
rier and an increase of vascular permeability that results
in macular edema [3]. Recent randomized, controlled
clinical trials have evaluated several treatment modal-
ities, including intravitreal triamcinolone acetonide [4]
and anti-vascular endothelial growth factor (VEGF)
therapy [5] for macular edema in patients with BRVO,
and both treatments have been reported to improve vis-
ual acuity after 12 months. We previously reported that
VEGF and inflammatory factors may contribute to the
pathogenesis of macular edema associated with BRVO
[6-9], which provides a rationale supporting the efficacy
of intravitreal triamcinolone (IVTA) and anti-VEGF ther-
apy. However, previous clinical studies only employed
measurement of visual acuity to evaluate visual func-
tion, even though macular edema usually involves the
larger macular area and not just the fovea. The Micro
Perimeter 1 (MP-1) is an instrument that combines
digital fundus imaging with automated perimetry
[10,11]. Unlike measurement of visual acuity that only
reflects foveal function, the MP-1 can evaluate both
the fovea and the larger macular area. We have previ-
ously found that retinal thickness and retinal volume
are more closely related to retinal sensitivity than to
visual acuity in BRVO patients who have macular
edema [12].
Optical coherence tomography (OCT) has revealed
that macular edema secondary to BRVO is frequently
associated with serous retinal detachment (SRD), as well
as with cystoid macular edema (CME) and inner retinal
thickening [13-15]. Some authors have reported that the
visual prognosis is poor for BRVO patients with SRD
[14,16-18]. It has been reported that the retinal thickness
is greater in SRD patients than CME patients [14], and
that IVTA decreases retinal thickness in SRD patients
[16]. Therefore, it may be important to investigate differ-
ences between SRD and CME. In addition, our previous
cross-sectional study showed that visual acuity and
macular thickness within the central 4°, 10°, and 20°
fields were significantly worse in the SRD group than in
the CME group, while macular sensitivity within the
central 4°, 10°, and 20° fields did not differ significantly
between the two groups [19]. However, little is known
about the influence of SRD in BRVO patients receiving
IVTA for macular edema. Therefore, we performed the
present study to assess the influence of SRD on changes
of visual acuity, macular sensitivity, and macular thick-
ness after IVTA in BRVO patients with macular edema.Methods
Subjects
This study was approved by the Institutional Ethics
Committee of Tokyo Women’s Medical University and
adhered to the tenets of the Declaration of Helsinki.
Written informed consent was obtained from each pa-
tient. IVTA was performed as part of standard care be-
cause it has been reported that macular edema and
visual acuity can be improved in BRVO patients by this
procedure [4]. At our hospital, the treatment options
for macular edema associated with BRVO include fol-
low-up, intravitreal anti-VEGF therapy, IVTA, laser
photocoagulation, and pars plana vitrectomy. This study
enrolled the patients in whom IVTA was selected as
the management option for CME, including SRD. We
prospectively studied 21 eyes of 21 consecutive patients
(mean age: 69.4 ± 9.6 years; 14 women and 7 men)
who had BRVO with macular edema and were treated
with IVTA. This prospective uncontrolled study was
conducted at the Department of Ophthalmology of
Tokyo Women’s Medical University between August
2008 and March 2011. Patients were diagnosed as hav-
ing hypertension if the systolic blood pressure was ≥140
mm Hg and diastolic blood pressure was >90 mm Hg,
or if the systolic pressure was ≥140 mm Hg at one
examination and the diastolic pressure was ≥90 mm Hg
on a different day, or if the patient was already taking
antihypertensive medication [20]. A diagnosis of hyper-
lipidemia was based on a total cholesterol≥240 mg/dL,
triglycerides≥160 mg/dL, low-density lipoprotein choles-
terol≥130 mg/dL, or use of cholesterol-lowering medi-
cation [20].
The inclusion criteria were eyes with a foveal thick-
ness greater than 300 μm and a visual acuity equal to
or less than 20/30. The exclusion criteria were (1) pre-
vious ocular surgery, (2) diabetes mellitus with diabetic
retinopathy, (3) previous macular laser photocoagula-
tion, (4) previous intravitreal injection of anti-VEGF
agents or triamcinolone acetonide, (5) a history of ocu-
lar inflammation, (6) marked retinal hemorrhage (in-
cluding macular bleeding involving the intrafoveal or
subfoveal spaces), (7) coexisting ocular disease (i.e.,
epiretinal membrane or glaucoma), and (8) retreatment
during the 6-month follow-up period. Twelve patients
had superior vein occlusion and 9 patients had inferior
occlusion.
All patients had undergone a comprehensive ophthal-
mologic examination, including best-corrected visual
acuity measurement, intraocular pressure determination,
indirect ophthalmoscopy, and slit-lamp biomicroscopy
with a contact lens before and at 3, and 6 months after
treatment. In addition, retinal sensitivity was investigated
by microperimetry, and retinal thickness was measured
by OCT.
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In the current study, 21 patients received IVTA under
local anaesthesia. For intravitreal therapy, the most com-
mon dosage of triamcinolone acetonide was 4.0 mg in a
volume of 0.1 ml. Injection of triamcinolone into the vit-
reous fluid was done via the pars plana at 3–4 mm pos-
terior to the limbus. All injections were performed with
a sterile technique, and prophylactic topical antibiotics
were applied for 1 week after injection. All patients were
followed up for at least 6 months postoperatively. Recur-
rence of macular edema was defined as an increase (by
>100 μm compared with the value at 3 months after ini-
tial IVTA) of foveal thickness when the thickness had
once decreased to <300 μm at 3 months after initial
IVTA [11]. Recurrence of macular edema was observed
in 3/21 eyes (14%), but the 3 patients did not want fur-
ther treatment.
Fundus examination
As baseline screening, patients underwent ophthalmos-
copy and biomicroscopic examination using a slit-lamp
with a fundus contact lens. They also underwent stand-
ard fundus color photography and fluorescein angiog-
raphy, which was performed with a Topcon TRC-50EX
fundus camera, an image-net system (Tokyo Optical Co.
Ltd., Japan), and a preset lens with a slit-lamp.
A masked grader independently assessed ischemic ret-
inal vascular occlusion on the fluorescein angiograms by
measuring the ischemic area of the retina with the pub-
lic domain Scion Image program, as reported previously
[6-8]. On digital photographs of the fundus, the optic
disc was outlined with a cursor and then its area was
measured, as was also done for the nonperfused area of
the retina. Then the nonperfused area was divided by
the disc area to calculate the severity of retinal ischemia.
Measurement of BCVA
Each patient underwent measurement of best-corrected
visual acuity (BCVA) with an SC-2000 System chart
(Nidek, Gamagori, Japan). BCVA was measured in deci-
mal units on a Landolt chart by the orthoptists. The
chart brightness was set at 80–320 cd/m2, and chart
contrast was more than 74%. The results were converted
to the logarithm of the minimum angle of resolution
scale (log MAR).
Measurement of optical coherence tomography
OCT was performed with an instrument from
Zeiss-Humphrey Ophthalmic Systems (Zeiss Stratus
OCT3, Carl Zeiss Meditec, Dublin, CA, USA) to
measure the foveal thickness. At each visit, all
patients underwent Stratus OCT examination in the
vertical cross-section with the instrument centered
on the fovea and in the fast macular thicknessmode. On these views, retinal thickness was defined
as the distance between the inner surface of the
neurosensory retina and the retinal pigment epithe-
lium. Foveal thickness was calculated as the average
retinal thickness within a circle of 500-μm radius
centered on the fovea. A retinal thickness map and
retinal volume map were obtained by scanning 6×6
mm (20°×20°) areas of the macular region, which
was divided into the following nine subfields: 1)
fovea, 2) superior inner macula, 3) nasal inner mac-
ula, 4) inferior inner macula, 5) temporal inner
macula, 6) superior outer macula, 7) nasal outer
macula, 8) inferior outer macula, and 9) temporal
outer macula [12]. The diameters of the central,
inner, and outer circles were 1, 3, and 6 mm, re-
spectively. In each region, measurement of retinal
thickness was automatically performed by computer
software.
In this study, we exchanged the superior and inferior
regions to separate the regions into those with occlusion
and those without it. As a result, the superior region was
always the occluded region and the inferior region was
always non-occluded. We then analyzed the occluded
and non-occluded regions separately. For the occluded
region, the mean macular thickness was determined
across four subfields (fovea, superior inner, nasal inner,
and temporal inner) covering the central 3×3 mm
(10°×10°), as well as across seven subfields (fovea, super-
ior inner, nasal inner, temporal inner, superior outer,
nasal outer, and temporal outer) covering the central
6×6 mm (20°×20°). For the non-occluded region, the
mean macular thickness was determined in one subfield
(inferior inner) covering the central 3×3 mm (10°×10°),
as well as across two subfields (inferior inner and infer-
ior outer) covering the central 6×6 mm (20°×20°). The
mean macular thickness was also determined in one
subfield (fovea) covering the central 1×1 mm (4°×4°).
SRD was defined as being present if OCT revealed
typical accumulation of subretinal fluid resulting in neu-
rosensory retinal detachment with low or absent reflect-
ivity anterior to a clearly distinguishable outer band,
irrespective of the coexistence of CME [21]. CME was
defined as present if OCT revealed hyporeflective intrar-
etinal cavities. All 11 patients with SRD had both SRD
and CME. Therefore, we classified the subjects into a
CME without SRD group (SRD (−) group) and a CME
with SRD group (SRD (+) group).
Functional mapping by microperimetry
Microperimetry with the MP-1 (Nidek, Gamagori, Japan)
is performed using an infrared fundus camera with a li-
quid crystal display controlled by special software. The
MP-1 software contains an automatic tracking system
for fundus movements; this evaluates every acquired
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with respect to a reference frame obtained by an infrared
camera at the beginning of the examination. Each pa-
tient underwent fundus-monitored microperimetry with
the MP-1 system (Nidek, Gamagori, Japan). Its software
performs automatic tracking of fundus movements and
evaluates every frame acquired for fundus shift in the x
and y directions relative to a reference frame obtained
with an infrared camera at the beginning of the examin-
ation. Microperimetry settings were identical for all
examinations: Goldmann III stimuli were presented in
random order according to a 4-2-1 double staircase
strategy. The stimulus intensity ranged from 0 to 20 dec-
ibels (dB) (0 dB corresponded to the strongest signal in-
tensity of 127 cd/m2) in 1-dB steps, and the duration of
each stimulus was 200 ms. The fixation target was varied
in size according to the patient's visual acuity. Retinal
sensitivity maps were obtained by using the macula 20
degrees program of the MP-1. During the examination,
background illumination was set at 1.27 cd/m2. Mean
retinal sensitivity was calculated from the sensitivity for
each of nine subfields on the retinal map generated by
OCT. We analyzed data for the occluded and non-
occluded regions separately. For the occluded region, we
determined the mean macular sensitivity at 23 sites in
the central 10° field (four subfields: fovea, superior inner,
nasal inner, and temporal inner) and at 44 sites in the
central 20° field (seven subfields: fovea, superior inner,
nasal inner, temporal inner, superior outer, nasal outer,
and temporal outer). For the non-occluded region, we
determined the mean macular sensitivity at 6 sites in the
central 10° field (inferior inner subfield) and at 13 sites
in the central 20° field (inferior inner and inferior outer
subfields). The mean macular sensitivity was also deter-
mined at five sites in the central 4° field.
Statistical analysis
All analyses were performed with SAS System 9.1 soft-
ware (SAS Institute Inc., Cary, North Carolina, USA).Table 1 Baseline clinical features of the two groups




Systolic blood pressure (mmHg) 134±13{
Diastolic blood pressure (mmHg) 83±8{
Hyperlipidemia 6
Duration of BRVO (months) 4.8±3.0{
Pattern of BRVO (major/macular) 7/3
Nonperfused area (disc areas) 39.0±43.8{
BRVO=branch retinal vein occlusion; SRD= serous retinal detachment. {Mean ± staResults are presented as the mean ± SD or as the fre-
quency. One-way or two-way repeated measures
ANOVA was used to evaluate changes in visual acuity,
macular sensitivity, and macular thickness. To examine
differences in the changes of parameters over time, trend
profiles were determined by repeated measures analysis.
Two-tailed P values of less than 0.05 were considered to
indicate statistical significance.
Results
The characteristics of the SRD (−) group and the SRD
(+) group are summarized in Table 1. Among the 21
patients with BRVO, 10 were assigned to the SRD (−)
group and 11 to the SRD (+) group. The mean age, fe-
male/male ratio, prevalence of hypertension, prevalence
of hyperlipidemia, duration of BRVO, pattern of BRVO,
and nonperfused area were similar in the SRD (−)
group and the SRD (+) group (P= 0.448, P= 0.537,
P= 0.890 P= 0.801, P= 0.287, P= 0.890, and P= 0.932,
respectively).
In both groups, IVTA achieved a reduction of clinical
macular edema that was confirmed by OCT. In both
groups, the mean macular thickness within the central
4° field decreased significantly from baseline to 3 and
6 months after IVTA (Figure 1a). In both groups, the
mean macular thickness within the 10° field of the
occluded region also decreased significantly from base-
line to 3 and 6 months after IVTA (Figure 1b). In the
SRD (−) group, the mean macular thickness within the
10° field of the non-occluded region did not decrease
significantly from baseline to 3 and 6 months after IVTA
(Figure 1c). On the other hand, the mean macular thick-
ness within the 10° field of the non-occluded region
decreased significantly from baseline to 3 and 6 months
in the SRD (+) group (Figure 1c). In both groups, the
mean macular thickness within the 20° field of the
occluded region showed a significant decrease from
baseline to 3 and 6 months after IVTA (Figure 1d).











Figure 1 (See legend on next page.)
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Figure 1 Trend profiles of the mean macular thickness after intravitreal injection of triamcinolone acetonide (IVTA) in BRVO patients
with macular edema. (a) Central 4° field (SRD (+), P<0.001; SRD (-), P<0.001; SRD (+) vs. SRD (-), P=0.227). (b) 10° field of the occluded region
(SRD (+), P<0.001; SRD (-), P<0.001; SRD (+) vs. SRD (-), P=0.019). (c) 10° field of the non-occluded region (SRD (+), P=0.001; SRD (-), P=0.165; SRD
(+) vs. SRD (-), P=0.372). (d) 20° field of the occluded region (SRD (+), P<0.001; SRD (-), P=0.001; SRD (+) vs. SRD (-), P=0.020). (e) 20° field of the
non-occluded region (SRD (+), P=0.085; SRD (-), P=0.058; SRD (+) vs. SRD (-), P=0.839).
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cantly from baseline to 3 and 6 months in either group
(Figure 1e).
In both groups, postoperative improvement of visual
acuity was noted after IVTA and persisted for at least
6 months. The visual acuity of the SRD (−) group
showed significant improvement from baseline to 3 and
6 months after IVTA (Figure 2). Likewise, the visual acu-
ity of the SRD (+) group showed significant improve-
ment from baseline to 3 and 6 months after IVTA
(Figure 2).
In both the SRD (−) group and the SRD (+) group,
improvement of macular function after IVTA was
detected with the MP-1. In both groups, the mean
macular sensitivity within the central 4° field increased
significantly from baseline to 3 and 6 months after
IVTA (Figure 3a). In both groups, the mean macular
sensitivity within the 10° field of the occluded region
also showed a significant increase from baseline to 3
and 6 months after IVTA (Figure 3b). However, the
mean macular sensitivity within the 10° field of the
non-occluded region did not show a significant increase
from baseline to 3 and 6 months after IVTA in either
group (Figure 3c). In both groups, the mean macularFigure 2 Trend profile of the mean visual acuity after
intravitreal injection of triamcinolone acetonide (IVTA) in BRVO
patients with macular edema. SRD (+), P=0.005; SRD (-), P=0.007;
SRD (+) vs. SRD (-), P=0.910.sensitivity within the 20° field of the occluded region
increased significantly from baseline to 3 and 6 months
after IVTA (Figure 3d). However, the mean macular
sensitivity within the 20° field of the non-occluded re-
gion did not show a significant increase from baseline
to 3 and 6 months after IVTA (Figure 3e).
There were no significant differences between the SRD
(−) group and the SRD (+) group with regard to the
trend profiles of macular thickness within the central 4°
field or within the 10° and 20° fields of the non-occluded
region (Figures 1a, c, and e). On the other hand, there
were significant differences between the two groups with
respect to the trend profiles of macular thickness within
the 10° and 20° fields of the occluded region (Figures 1b
and d). The trend profile of visual acuity showed no sig-
nificant difference between the two groups (Figure 2).
There were also no significant between-group differ-
ences with regard to the trend profiles of macular sensi-
tivity within the central 4° field or within the 10° and 20°
fields of the occluded and non-occluded regions
(Figures 3a-e).
Up to 6 months after IVTA, two of the 21 patients
(9.5%) showed an increase of intraocular pressure, but
this could be controlled by a change of medication. Neo-
vascular glaucoma was not detected in any of the
patients, so trabeculectomy or shunt surgery was not
performed. There were also no new cases of cataract or
progression of existing cataracts and no infectious
endophthalmitis after IVTA.
Discussion
In the present study, we found that the mean macular
thickness within the central 4° field and within the 10°
and 20° fields of the occluded region showed a signifi-
cant decrease from baseline to 3 and 6 months after
IVTA in both the SRD (−) group and the SRD (+) group.
These results suggest that macular thickness is improved
by IVTA in BRVO patients with SRD, as has already
been demonstrated in BRVO patients without SRD. SRD
is thought to be caused by transudation of extracellular
fluid into the subretinal space [13-15,22,23], with the site
of detachment being determined by the foveal architec-
ture, especially the Müller cell cone [14]. When the bar-
rier function of the external limiting membrane (ELM)
is lost due to traction on the Müller cell cone, intraret-
inal fluid will move into the subretinal space, resulting
Figure 3 (See legend on next page.)
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Figure 3 Trend profiles of the mean macular sensitivity after intravitreal injection of triamcinolone acetonide (IVTA) in BRVO patients
with macular edema. (a) Central 4° field (SRD (+), P=0.006; SRD (-), P=0.016; SRD (+) vs. SRD (-), P=0.518). (b) 10° field of the occluded region
(SRD (+), P=0.007; SRD (-), P=0.018; SRD (+) vs. SRD (-), P=0.581). (c) 10° field of the non-occluded region (SRD (+), P=0.130; SRD (-), P=0.168; SRD
(+) vs. SRD (-), P=0.468). (d) 20° field of the occluded region (SRD (+), P=0.022; SRD (-), P=0.049; SRD (+) vs. SRD (-), P=0.526). (e) 20° field of the
non-occluded region (SRD (+), P=0.230; SRD (-), P=0.145; SRD (+) vs. SRD (-), P=0.782).
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[14]. Triamcinolone acetonide is thought to improve
macular edema by decreasing retinal capillary permeabil-
ity via an effect on tight junctions [24], or it could in-
hibit the signaling cascade involving VEGF and the
VEGF receptor that increases microvascular permeability
[25,26]. Corticosteroids may also prevent the production
of various inflammatory molecules [27-29] that promote
leukocyte adhesion and breakdown of the blood-retinal
barrier [30,31]. We previously reported that an excessive
increase of vascular permeability secondary to upregula-
tion of VEGF and sICAM-1 may contribute to the devel-
opment of SRD in BRVO patients [21]. Accordingly, a
decrease of retinal capillary permeability after IVTA may
relieve traction on the Müller cell cone, resulting in a
decrease of SRD. Thus, IVTA may be effective for redu-
cing macular thickness in BRVO patients with SRD as
well as those without SRD.
We also found that visual acuity and macular sensitiv-
ity within the central 4° field and within the 10°, and 20°
fields of the occluded region were improved significantly
from baseline to 3 and 6 months after IVTA in both the
SRD (−) group and the SRD (+) group. These results
suggest that visual acuity and macular sensitivity can
also be improved by IVTA in BRVO patients with SRD
as has been shown in BRVO patients without SRD. In
eyes with BRVO, fluid leaking from affected retinal ca-
pillaries accumulates around the fovea and produces ret-
inal thickening, which may cause the internal limiting
membrane at the clivus of the fovea to protrude with
formation of foveal cystoid spaces [14]. The cells in the
Müller cell cone would then be stretched perpendicu-
larly in the walls of the foveal cystoid spaces. When fluid
leakage increases, further traction on the Müller cell
cone would lead to traction on the inner and outer seg-
ments of the foveal photoreceptors, resulting in a small
retinal detachment at the fovea [14]. Subsequently, SRD
would develop when the ELM barrier breaks down at
the fovea [14]. Loss of the ELM barrier often leads to
damage to photoreceptors in the outer segment, result-
ing in impairment of macular function (visual acuity and
macular sensitivity). These reports and our results sug-
gest that reduced traction on the Müller cell cone due to
a decrease of vascular permeability after IVTA can alle-
viate damage to foveal photoreceptors in the outer seg-
ment by restoring the ELM barrier, resulting inimprovement of macular function (visual acuity and
macular sensitivity) in BRVO patients whether or not
they have SRD.
Interestingly, this study demonstrated a significant dif-
ference in the trend profiles of macular thickness within
the 10° and 20° fields of the occluded region between the
SRD (−) group and the SRD (+) group, while there were
no significant differences between the two groups with
regard to the trend profiles of visual acuity and macular
sensitivity within the central 4° field and within the 10°
and 20° fields of the occluded and non-occluded regions.
In other words, macular thickness within the 10° and 20°
fields showed a better response to IVTA in BRVO
patients with SRD than in those without SRD. The
greater improvement of morphology in the SRD (+)
group compared with the SRD (−) group may have been
due to the fact that SRD causes more extensive morpho-
logic change compared with CME, thus allowing a
stronger response to IVTA. On the other hand, visual
acuity and macular sensitivity showed similar trend pro-
files after IVTA regardless of the presence or absence of
SRD. This discrepancy between the trend profiles of
macular thickness versus visual acuity and macular sen-
sitivity may have arisen because SRD did not have much
influence on macular function since it is caused by tran-
sudation of extracellular fluid into the subretinal space
[13-15] and there is little traction on the Müller cell
cone in the macular region [14]. Thus, our results sug-
gest that IVTA may achieve more improvement of
macular morphology in BRVO patients with SRD than
in those without SRD, while this therapy may have a
similar influence on macular function in BRVO patients
with or without SRD. However, further investigation will
be needed to clarify the relation between the changes of
macular function and morphology after IVTA.
The limitations of this study were a short follow-up
period, a small sample size, and lack of a control group.
Although the results of long-term follow up could be
interesting, additional treatment with further IVTA or
anti-VEGF agents for recurrence may bias the outcome.
Despite this risk, further investigations should be done
to evaluate the long-term outcome in the future. In
addition, we could not evaluate the relation between
macular function and the inner segment/outer segment
ratio of the photoreceptor layer because we did not have
access to spectral domain OCT.
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There was a significant difference between the SRD (−)
group and the SRD (+) group with respect to the trend
profiles of macular thickness within the 10° and 20°
fields of the occluded region, but there were no signifi-
cant between-group differences with regard to the trend
profiles of visual acuity and macular sensitivity within
the central 4° field and within the 10°, and 20° fields of
the occluded and non-occluded regions. These results
suggest that IVTA may achieve more marked improve-
ment of macular morphology in BRVO patients with
SRD than in those without SRD, while this therapy may
have a similar effect on macular function irrespective of
the presence of SRD.
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